{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-23-000079","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2023-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.555188+00:00","generated_at":"2026-06-08T08:51:39.997719+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Amphastar Q3 revenue up 50% to $180.6M; GAAP EPS $0.91, adj. $1.15","bullets":["Net revenues of $180.6M for Q3 2023, up from $120.1M in Q3 2022 (50% increase).","GAAP net income $49.2M ($0.91 diluted EPS) vs $15.9M ($0.30) a year ago.","Adjusted non-GAAP net income $61.9M ($1.15 diluted EPS) vs $20.2M ($0.38).","CEO attributes growth to diabetes portfolio, including BAQSIMI acquisition and generic glucagon.","Nine-month net revenues $466.3M vs $364.0M; GAAP net income $101.4M vs $57.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-23-000079","json":"https://secwatch.observer/filing/0001297184-23-000079.json","markdown":"https://secwatch.observer/filing/0001297184-23-000079.md","text":"https://secwatch.observer/filing/0001297184-23-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000079/0001297184-23-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000079/amph-20231108x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T08:51:39.997719+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"be9d3e2a00cae74c818097c4681b35610c520f0b","claim":"Amphastar Pharmaceuticals, Inc. reported three months ended September 30, 2023 results: revenue $180.6 million, net income $49.2 million, or $0.91 per share, EPS $0.91 per share.","evidence_excerpt":"in such a filing. ​ --- EX-99.1 (EX-99.1) --- ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 23 ​ Reports Net Revenues of $180.6 Million for the Three Months Ended September 30, 2023 ​ RANCHO CUCAMONGA, CA – November 8, 2023 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718423000079/0001297184-23-000079-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2023"},{"label":"Revenue","value":"$180.6 million"},{"label":"Net income","value":"$49.2 million, or $0.91 per share"},{"label":"EPS","value":"$0.91 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}